Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$38.96 - $42.75 $1.95 Million - $2.14 Million
50,000 Added 6.7%
796,440 $32.6 Million
Q1 2024

May 15, 2024

BUY
$40.88 - $43.27 $30.5 Million - $32.3 Million
746,440 New
746,440 $31.6 Million

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track P Schoenfeld Asset Management LP Portfolio

Follow P Schoenfeld Asset Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of P Schoenfeld Asset Management LP, based on Form 13F filings with the SEC.

News

Stay updated on P Schoenfeld Asset Management LP with notifications on news.